| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785341 | Brachytherapy | 2018 | 8 Pages |
Abstract
IVBT is cost-effective compared with observation after TH/BSO for HIR endometrial carcinoma by commonly accepted willingness-to-pay thresholds.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
John M. Stahl, Shari Damast, Trevor J. Bledsoe, Yi An, Vivek Verma, James B. Yu, Melissa R. Young, Nataniel H. Lester-Coll,